Introduction
Prototheca is an alga that lacks chlorophyll. It is common in the environment but rarely causes infection in humans or animals. We will limit our scope to human infections. Prototheca biology and ecology have been reported elsewhere [1 -7] . Only two species have caused human disease: Prototheca wickerhamii (Tubaki and Soneda) and Prototheca zopfi i (Kruger) [8, 9] . We report a case of P. wickerhamii wound infection, and present a review of the world literature of human Prototheca infections published through June 28, 2011. Recent nucleic acid research has raised questions about the taxonomy of Prototheca species [10 -16] . A new taxonomy has not yet been established. For the present work, we will continue to use the traditional species classifi cation of Prototheca based on morphology and on explored the right wrist on August 23, and a histological diagnosis of fungus, probably chromoblastomycosis, was made in the absence of culture. Ketoconazole was given daily as 200 mg for 12 days, 400 mg for 22 days, and 200 mg for the next 37 days. Review of histological specimens established a defi nitive diagnosis of protothecosis. Ketoconazole was continued and symptoms resolved. The patient returned to work November 26 but, by early December, swelling and vague discomfort occurred in the right wrist, resolving when off work a few days, and recurring upon return to work.
Repeat surgery of the right wrist on June 25, 1990 removed a yellowish mass, but yellowish material extending up the tendons could not be entirely removed. Histopathology showed granulomatous infl ammation and Prototheca species, and Prototheca wickerhamii was cultured. Since all infected material could not be removed, intravenous amphotericin-B deoxycholate was given 2 or 3 times weekly between July 6 and November 8, 1990 , in 38 doses of 22 mg average for a total of 835 mg. Oral tetracycline was included from August 6 -19, at doses ranging from 500 mg 4 times a day, to 250 mg twice a day. A second course of 250 mg 3 times a day, from November 1 -11 was given. Since then, the patient has had occasional aching in the wrists, probably repetitive motion syndrome. We last saw her March 6, 2006, and on May 24, 2011 she reported ' My wrist is doing fi ne. ' Based on over 20 years of follow-up, we consider her cured.
Laboratory fi ndings
The resected tissue contained numerous granulomas with multinucleated giant cells and mononuclear cells. These were present in the dermis and subcutaneous tissues. The Prototheca organisms were present within the infl ammatory infi ltrate and occasionally within giant cells. Periodic acid Schiff and Gomori methenamine silver stains highlighted the organisms as shown in the Supplementary  Fig. 1 to be found online at http://www.informahealthcare. com/mmy/doi/10.3109/13693786.2012.677862 online only. Primary smears were prepared for Giemsa staining. Portions were distributed to four media: (1) Emmons modifi cation of Saboraud dextrose agar (Becton Dickinson Microbiology Systems, Cockeysville, Maryland) with gentamicin added, (2) Sabhi agar (Becton Dickinson) with chloramphenicol added, (3) Mycosel agar (Becton Dickinson) with chloramphenicol and cycloheximide, and (4) Guizotia abyssinica agar (also known as bird seed agar, noncommercial) with chloramphenicol added. Visible growth was evident by the third day of incubation at 30 ° C, and occurred on all primary media except Mycosel (contains cycloheximide). Colonies were soft, cream colored, and grossly indistinguishable from yeast colonies. However, on the Giemsa-stained primary smears of clinical material, and on Giemsa and lactophenol cotton blue preparations from the colonies, spherical structures of various sizes containing internal bodies were observed, and revealed the identity of the isolate to be a Prototheca species rather than a yeast. We identifi ed our P. wickerhamii isolate to species level using morphological and biochemical criteria. Morphologically, this culture isolate produced sporangia that were predominantly round, lacked capsules, readily formed endospores, and typically were in the size range 7 -13 μ m, all characteristics of P. wickerha ii [21 -23] . The biochemical pattern of this isolate identifi ed it as P. wickerhamii. We used the Vitek YBC card (bioMérieux, F-69280 Marcy l'Etoile, France) for biochemical assimilation testing. This isolate assimilated glucose, galactose, and trehalose, a pattern characteristic of P. wickerhamii [6,10,17,18,21 -23] . Two of the authors (T. A. Shahan and R. S. Pore) tested the isolate for susceptibility to antimicrobial drugs using the methods previously described [24, 25] . Minimum inhibitory concentrations (MIC) were Ͼ 20 μ g/ml for ketoconazole, Ͼ 20 for fl uconazole, Ͼ 20 for tetracycline, 0.5 for gentamicin, 1.0 for tobramycin, 0.5 for amphotericin-B, and 2.0 for polymixin-B.
Methods for literature review and analysis
We found publications by searches in MEDLINE ( Tokyo, Japan, May 25 -29, 2009 ]. We searched the reference lists of all articles we found for citations to other articles. We accepted publications in all languages, and asked help from translators when needed. We accepted any human protothecosis case published before June 28, 2011, and reported in narrative form, but did not accept any case that was only listed in a table in a review article without a citation to a case report.
No two patients were treated exactly alike. In order to analyze the effectiveness of treatment, we grouped the cases into groups with similar treatments. If a treatment was actually a combination of treatments, we assigned it to a group based on what we considered the most important component(s). We made separate groups for treatments used at least 5 times, and special separate groups for amphotericin-B topical, for voriconazole, for debridement, and for none (see Tables 1 and 3, and Supplementary Table  1 to be found online at http://www.informahealthcare.com/ mmy/doi /10.3109/13693786.2012.677862) . Other treatments used less than 5 times were put into the ' other ' group. In Table 1, we list the treatment as ' other. ' In the  Supplementary online version of Supplementary Table 1 , the treatment is listed as ' other, ' and then specifi ed. In Table 3 , we list the success rate for the entire ' other ' group. In some cases, the authors noted that the fi rst treatment(s) failed, and they changed to another treatment. We considered the treatments separately.
For analysis of predisposing factors, we separated the cases as to whether or not the host was immunocompromised, or treated with corticosteroids, or both, before the onset of protothecosis. We considered a patient immunocompromised if the patient had primary immunodefi ciency, organ transplant, cancer treated with chemotherapy, alcoholism, diabetes mellitus, chronic renal failure, acquired immune defi ciency syndrome, chronic mucocutaneous candidiasis, or an auto-immune disease. Among autoimmune diseases we included rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, and myasthenia gravis. If the case report gave no information about underlying disease, immunocompromise, or preceding corticosteroid use, we assumed that the patient did not have these conditions. To test for trends over time, we divided the time since the fi rst report of human protothecosis into three roughly equal time periods: 1964 -1979, 1980 -1995, and 1996 -2011 . We consider our case as reported in 2011. We listed the number of human protothecosis cases reported in each of these three time periods, fi rst for all 160 cases, and then separately by whether or not the host was immunocompromised, or treated with corticosteroids, or both, before the diagnosis of protothecosis. To test whether the incidence of reports of protothecosis has changed over time, we proposed the null hypothesis that the incidence of reports of protothecosis has not changed over time, and tested by the chi-square test, where the expected value for each of the three periods is the average of the values in the three periods [26] .
For analysis of treatment effectiveness, we grouped outcomes into four groups. The ' success ' group included cure and improvement. The ' failure ' group included stabilization during treatment but no improvement, improvement during treatment but recurrence later, and progression of disease on treatment. The ' unknown ' group included treatments with no information about outcome. The ' unevaluable ' group included treatments for which the information given did not allow an assessment of treatment effectiveness. In Table 3 , we analyze effectiveness of treatments, using the group assignments for treatment and outcome. We list percent success. For line items with up to 30 cases, we calculated 95% confi dence intervals from tables of confi dence intervals for the binomial distribution [27] . For line items with over 30 cases, we calculated 95% confi dence intervals using the normal approximation to the binomial distribution [27] . We list the 95% confi dence interval in parentheses after the percent success. In comparing one treatment with another, we used Fisher ' s exact test, calculated by GraphPad InStat version 3.06 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com. We performed calculations using Microsoft Access and Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA).
Results

Prototheca as a pathogen
Our analysis of human protothecosis is based on 160 cases: 159 cases we found published before June 28, 2011, plus our case reported here. These 160 cases are all cases of Prototheca causing human disease, and do not include any cases of Prototheca as a colonizer. In all 160 cases, Prototheca was identifi ed by histology, by culture, or by both. Histology was positive in 134 cases, negative in 6 cases, not done in 20 cases. Culture was positive in 129 cases, negative in 16, and not done in 15. All the cases that were identifi ed to the species level were either P. wickerhamii or P. zopfi i . Of the 160 cases, 115 were P. wickerhamii , 11 were P. zopfi i , and 34 were not speciated.
The cases were distributed worldwide among the continents: Asia 63 cases, North America 56, Europe 20, South America 11, Africa 3, Australia 3, Central America 2, and New Zealand 2. Sex distribution was about equal: 86 male, 73 female, and 1 case where sex was not reported. Of the 160 reported cases, age was reported in 156. We did not fi nd any fetal or neonatal cases of human protothecosis, but infection occurred at all ages after the neonatal period, ranging from 78 days ( (case 116), pulmonary infection (case 121), skin plus olecranon bursa (case 147), and lymphadenitis (case 155); 2 cases of central vein catheter infection (cases 58 and 122); and 3 cases of meningitis (cases 63, 97, and 141). The patients with peritonitis were all on peritoneal dialysis for chronic renal failure.
In Table 1 , we consider each of the 160 protothecosis cases individually. Table 1 contains information (if known) for each case about the year the case was fi rst published, patient ' s age and sex, species of Prototheca , geographic location, whether the patient was immunocompromised, type of protothecosis, whether the patient was treated with corticosteroid before the diagnosis of protothecosis, treatment of the protothecosis, and outcome. In the ' treatment ' column, we list the treatment group(s) to which we assigned the treatment(s) the patient received. In the Supplementary online version of Supplementary Table 1 we give further information about the type and duration of treatment, if available. Table 2 categorizes the protothecosis cases as to site of infection, and whether the patient had been treated with corticosteroids or had been diagnosed with a pre-existing immunocompromising condition. Table 2 also analyzes separately the protothecosis cases reported in three roughly equal time periods since the fi rst reported case: 1964 -1979, 1980 -1995, and 1996 -2011 . Reports of protothecosis have become more common over time, but most of the increase 
Treatments for Prototheca
The 160 cases received 195 treatments. Some cases received more than one treatment. For 14 cases, the reports do not give the type of treatment. For these cases, we list the treatment as ' unknown ' in Table 1 , and we do not consider these treatments in analysis of treatment effectiveness. Eliminating the 14 unknown treatments leaves 181 known treatments. Outcomes for these treatments were unknown for fi ve treatments and unevaluable for another nine treatments. We eliminated the 14 treatments with unknown or unevaluable outcomes from consideration of treatment effectiveness. This leaves 167 evaluable treatments. Of the 167 evaluable treatments, 119 succeeded, and 48 failed, overall treatment success rate 71% (64 -78%) (Table 3) .
Intravenous amphotericin-B alone was one of the common and effective treatments for Prototheca infections. There were 26 treatments in the amphotericin-B IV treatment group. Of these 26 treatments, 20 succeeded and 6 failed, for a success rate of 77% (56 -91%).
There were 62 patients treated with a systemic azole alone, allowing evaluation of the particular azole. There were 32 treated with itraconazole, with 21 successes, and 11 failures for a success rate of 66% (49 -82%). There were 15 treated with fl uconazole, with 10 successes, and 5 failures for a success rate of 67% (38 -88%). There were 11 treated with ketoconazole, with 6 successes, and 5 failures for a success rate of 55% (23 -83%). There were four treated with voriconazole, with three successes, and one failure for 15 cases in the fi rst period, 20 in the second, and 17 in the third ( P Ͼ 0.50). In contrast, Table 2 shows marked increases over time in the numbers of Prototheca infections in patients with immunocompromise but no steroid treatment ( P Ͻ 0.001), those with steroid treatment but no immunocompromise ( P Ͻ 0.001), and those with both immunocompromise and steroid treatment ( P Ͻ 0.005). These P values are interesting, but we are limited in claiming ' statistical signifi cance ' because we did not formulate the hypothesis before we collected the data [26, 27] . Corticosteroids had the strongest effect on wound infections, with 6 of the 10 reported wound infections occurring in patients treated with corticosteroids. This includes our own case.
In vitro susceptibilities
Leimann et al ., and Lass Fl ö rl and Mayr have reviewed in vitro susceptibilities to individual drugs [19, 20] . Almost all a success rate of 75% (19 -99%) . The success rates are highest for amphotericin-B IV, intermediate for itraconazole and fl uconazole, and lowest for ketoconazole, but the confidence intervals are wide and overlap. The number treated with voriconazole is too small to compare rates. Another 14 cases were treated with amphotericin-B IV plus something else: tetracycline in cases 29, 37, 109, and 160; doxycycline in case 60; itraconazole in cases 95, 133, 141, and 152 ; ketoconazole in case 48; and excision in cases 62 and 92; and all these treatments succeeded. Amphotericin-B IV was combined with 5-fl uorocytosine in case 63, and with rifampin in case 148, and both these treatments failed. Of these 14 treatments, 12 succeeded, and 2 failed, success rate 86% (57 -98%).
Analogous to the 14 treatments combining amphotericin-B IV plus something else, there were 11 treatments combining itraconazole plus something else: topical tioconazole and oral doxycycline in case 75; fl uconazole in cases 94 and 101; amphotericin-B IV in cases 95, 133, 141 , and 152; amphotericin-B bladder irrigation and oral terbinafi ne in case 116; and voriconazole in case 135. Case 154 received two treatments: oral itraconazole plus topical ketoconazole, which failed; and oral itraconazole plus topical heat, which succeeded. Of these 11 treatments, the only failure was the fi rst treatment of case 154. So 10 of 11 treatments succeeded, with a success rate of 91% (59 -100%).
The total of all treatments with amphotericin-B IV, either alone or plus something else, comes to 40 treatments, with 32 successes and 8 failures, for a success rate of 80% (68 -92%). The total of all treatments with itraconazole, either alone or in combination with anything else, comes to 43 treatments, with 31 successes and 12 failures, for a success rate of 72% (59 -85%). Cases 95, 133, 141, and 152 were treated with the combination of amphotericin-B and itraconazole, so they were counted in both the amphotericin-B IV plus anything group and the itraconazole plus anything group.
Cases 129 and 159 failed itraconazole and later failed amphotericin-B IV, so cases 129 and 159 were counted as both itraconazole failures and amphotericin-B IV failures. Not only has the number of patients failing amphotericin-B IV been less than the number failing itraconazole, but also the types of patients failing amphotericin-B IV have been different from the types of patients failing itraconazole. Of the six patients who failed amphotericin-B alone, fi ve were immunocompromised (cases 124, 125, 129, 145, and 159) . Only case 54 was not immunocompromised. All six of these patients had disseminated infection, and all six died. The two failures for amphotericin-B in combination were case 63 and case 148, both immunocompromised. Case 63 had meningitis and died [34] . Case 148 had developed a P. wickerhamii infection at a former Hickman catheter site, with a positive blood culture. She failed treatment with AmBisome (liposomal amphotericin-B) plus rifampin. She was eventually cured with a regimen of voriconazole plus gamma interferon. This is the only case who received rifampin, either alone or in combination. Also, this was the only case which failed treatment with amphotericin-B IV, alone or in combination, and was later salvaged by a regimen that did not contain amphotericin-B [35] .
The 11 itraconazole failures were cases 78, 83, 111, 116, 123, 126, 129, 132, 140, 155, and 159 . Cases 129 and 159 were also amphotericin-B IV failures (see above). Only one case failed itraconazole in combination. Case 154, a skin infection, received two treatments: oral itraconazole plus topical ketoconazole, which failed; and oral itraconazole plus topical heat, which succeeded.
Of the eight patients who failed amphotericin-B IV, alone or in combination, seven of eight had underlying immunocompromising disease. Types of protothecosis included seven disseminated and one meningitis. Eventual outcome was death in seven of the eight. The only one who survived had failed amphotericin-B IV plus rifampin, and was salvaged with voriconazole plus gamma interferon. In contrast, of the 12 patients who failed itraconazole, alone or in combination, only 6 of the 12 had underlying immunocompromising disease. Types of protothecosis included only 2 disseminated, 8 skin cases, 1 urinary tract infection, and 1 lymphadenitis. Only 2 of the 12 died. Other eventual outcomes included 6 cured, 2 improved, 1 unknown, and 1 unevaluable. Of the 8 who were eventually cured or improved, 2 were salvaged by amphotericin-B IV, 1 was salvaged by amphotericin-B bladder irrigation plus oral itraconazole plus oral terbinafi ne, 2 were salvaged by systemic fl uconazole, 1 was salvaged by systemic voriconazole, 1 was salvaged by topical lanoconazole, and 1 was salvaged by oral itraconazole plus local heat. The fl uconazole and ketoconazole failures were similar to the itraconazole failures.
Experience with the new azole, voriconazole, has been limited and mixed. As listed in Table 3 , there were four patients treated with voriconazole alone, with three successes (cases 132, 147, and 148) and one failure (case 151). We included case 148 as a success for voriconazole, even though the voriconazole was combined with gamma interferon. Case 135 was successfully treated with a month of itraconazole followed by a month of voriconazole [36] . It is diffi cult to say how much the voriconazole versus the itraconazole contributed to the success, and we did not include case 135 as a voriconazole success in Table 3 . Case 125 was not actually treated with voriconazole after diagnosis of protothecosis, but developed P. zopfi i infection while he was already taking voriconazole 400 mg daily for aspergillosis [37] . His P. zopfi i isolate was resistant to voriconazole, with MIC Ͼ 64 μ g/ml. After diagnosis of protothecosis, the patient was treated with amphotericin-B IV, but failed treatment and died. At autopsy, P. zopfi i was cultured from lung, kidney, heart, and liver.
With the azoles, in vitro resistance has not always predicted clinical failure. In case 31, ketoconazole cured the infection, even though the Prototheca was resistant to ketoconazole in vitro , with MIC ϭ 32 μ g/ml [38] . In case 126, the MICs were 2 μ g/ml for itraconazole, and Ͼ 64 μ g/ml for fl uconazole; but the infection persisted on itraconazole treatment, and was cured by fl uconazole [19] . Regarding the issue of in vitro susceptibility testing, Leimann et al ., wrote: ' There is no direct correlation between in vitro activity and clinical response; furthermore, it is not clear whether susceptibility tests to antifungal agents are reliable for evaluating algae ' [19] .
There were 18 evaluable treatments consisting of complete surgical excision alone. These included 9 patients with olecranon bursitis, 7 with skin infections, 1 with larynx infection, and 1 with wound infection. Of these 18 treatments, 16 succeeded, success rate 89% (65%-99%). Both failures were skin cases: cases 91 and 132. There were 12 cases of Prototheca olecranon bursitis. Of these 12 cases, 2 were treated by excision, but outcome was not reported (cases 25 and 30); so they cannot be considered in the evaluation of treatment effectiveness. This leaves 10 evaluable cases. Of these 10 cases, 8 were treated by excision as the only treatment, and excision succeeded in all 8 cases (cases 6, 7, 10, 22, 23, 35, 43, and 50) . Case 73 failed both systemic doxycycline and local intrabursal amphotericin-B, and then was cured by excision [39] . So excision was used in a total of 9 cases of Prototheca olecranon bursitis, and cured all 9 cases, success rate 100% (66 -100%). Case 39 was the only olecranon case not treated by excision. He was a poor surgical risk, and was cured with intrabursal injections of amphotericin-B, but this caused bulky scarring [40] .
While total excision had a high success rate, incision and drainage or simple debridement did not. Case 24, a wound infection, was cured without any medical treatment, but it took multiple debridements [41] . In case 104, the skin infection recurred after debridement, and was later cured with amphotericin-B IV [42] . In both case 55 and case 160 (the case reported in this publication), the Prototheca infection recurred after debridement plus oral ketoconazole, and required amphotericin-B, alone or with tetracycline, for cure [43] .
Topical amphotericin-B was used in six evaluable treatments. It was used alone in three cases. It succeeded in cases 9 and 15, and failed in case 19, success rate 67% (9 -99%) [44 -46] . Topical amphotericin-B was used in combination in three cases. It was used together with several other agents in case 3, and it failed [47, 48] . It succeeded together with oral tetracycline in case 47, and together with oral fl uconazole in case 77 [49, 50] . Considering all six cases treated with topical amphotericin-B, alone or in combination, it succeeded in four cases, success rate 67% (22 -96%). For Table 3 , cases 3, 9, 15, and 19 are classifi ed in the ' amphotericin-B topical ' group, and cases 47 and 77 are classifi ed in the ' other ' group. Local injection of amphotericin-B was tried in six cases (cases 19, 39, 73, 110, 116, and 132) , but succeeded on only two (cases 39 and 110), success rate 33% (4 -78%) [39,40,46,51 -54] . Case 116 actually got three treatments for Prototheca urinary infection. First she got itraconazole orally for 3 months. This failed. Second she got amphotericin-B 50 mg/liter instilled in the bladder 6 times over 3 weeks. This failed. Third she got continuous fl ushing of the bladder with amphotericin-B 50 mg/liter plus oral itraconazole 200 mg twice a day plus oral terbinafi ne 250 mg once a day, for 7 days. This last treatment cured her [52] . Because the second treatment consisted only of amphotericin-B instillation into the bladder, and the third treatment had three components, we counted the second treatment as a failure for amphotericin-B local injection, and we did not count the third treatment either as a success or a failure for amphotericin-B local injection.
Topical azoles were reported to have been used in four cases, with three successes and one failure. The three successes were ketoconazole 2% cream for fi ngernails in case 59, lanoconazole ointment for skin infection in case 123, and oxiconazole 1% solution for fi ngernails in case 137. All three of these topical azole treatments succeeded [55 -57] . The only failure was the fi rst treatment of case 154: oral itraconazole plus topical ketoconazole cream for a skin infection [58] . Local injections of an azole have been reported once -fl uconazole local injections for a skin infection in case 106, and they succeeded [59] .
Other medicines besides amphotericin-B and the azoles have been used in few cases, and/or have had unimpressive results. These include tetracyclines, aminoglycosides, echinocandins, terbinafi ne, and polymixins. These have been used in combinations more often than alone.
Topical heat was tried in three cases and succeeded in two cases. Case 53 was treated with several agents, including topical heat, and the combined treatment succeeded [60, 61] . Case 77 was treated with oral KI and topical heat, and this treatment failed [50] . Case 154 was treated with oral itraconazole and topical heat, and this treatment succeeded [58] . The species was P. wickerhamii in cases 53 and 154, and not speciated in case 77.
Duration of treatment has varied, and some case reports have not specifi ed duration. Cure has been achieved with azoles at durations ranging from 2 weeks (case 72) to 1 year (case 126) [19, 62] . Cure has been achieved with amphotericin-B at durations ranging from 10 days (cases 41 and 103) to 5 months (case 67) [63 -65] .
There were four cases that got no treatment at all. Case 21 was a skin infection that improved without treatment [66] . Case 131, a skin infection, had both cirrhosis and hepatocyte carcinoma. The authors were reluctant to use potentially hepatotoxic medications, so they chose to observe the patient without treatment. Over 3 months the skin lesion regressed, and it did not recur over 9 months of follow-up observation [67, 68] . In case 143, a rash had appeared on the patient ' s right arm 3 years previously. The rash had been treated with topical steroid, but the rash worsened. The authors diagnosed skin protothecosis, and stopped the topical steroid. The rash improved without any other treatment [69] . In case 65, a woman with Sheehan ' s syndrome on chronic corticosteroid therapy developed apparent right arm cellulitis and sepsis syndrome and died. Blood cultures drawn before she died turned positive after she died and grew P. wickerhamii [70] .
In all fi ve cases of protothecosis involving a foreign body, such as a peritoneal dialysis catheter (cases 41, 57, and 60) or an intravenous line (cases 58 and 79), the foreign body was removed as part of the treatment [63,71 -74] .
Analyzing evaluable treatments by infection type (Table 3) , fi ngernail infection had the best treatment success rate, disseminated infection had the worst, and the other infection types were intermediate. The differences were not statistically signifi cant. Analyzing evaluable treatments by predisposition, immunocompromising underlying disease was associated with lower protothecosis treatment success rates, but the differences were not statistically signifi cant. Success rates were for cases with neither immunocompromise nor steroid 74% (62 -86%), for steroid but no immunocompromise 81% (69 -93%), for immunocompromise but no steroid 70% (51 -85%), and for both immunocompromise and steroid 59% (43 -74%). Analyzing evaluable treatments by Prototheca species, there was a trend toward better outcome with P. wickerhamii than with P. zopfi i , but the differences were not statistically signifi cant. Treatment success rates were for P. wickerhami i 67% (59 -76%), for P. zopfi i 54% (25 -81%), and for unspeciated cases 94% (85 -100%).
Discussion
Prototheca are common in nature, and humans are undoubtedly often exposed to them; but Prototheca appear to have relatively little ability to infect the human host. Trends over time demonstrate that as corticosteroid use has become more common, and the pool of surviving immunocompromised patients has increased, reports of protothecosis have become more common. Most of this rise has been in steroid-treated and/or immunocompromised patients, with no signifi cant rise in normal hosts. We suspect that Prototheca is a low grade pathogen in the normal host, and that corticosteroid use or immunocompromise greatly increase host susceptibility to Prototheca . In experimental animals, pretreatment with corticosteroids has made the animals more susceptible to infection when challenged with Prototheca [17, 75, 76] .
Cases 53, 88, and 143 are interesting examples of probable steroid effect. Case 53 had an underlying chronic skin disease, and was getting a prolonged course of oral dexamethasone. Then the patient developed Prototheca skin infection as a secondary skin disease [60] . Case 88 suggests that not only may preceding corticosteroids predispose to Prototheca infection, but continuing corticosteroids may hinder the treatment of protothecosis. Their patient ' s lesion had improved only slightly after 12 weeks of itraconazole 200 mg per day. Then they discovered that she was continuing to apply topical steroid cream, and they recommended she stop the steroid and instead apply amoralfi ne cream 0.25%, and continue the itraconazole. After another 4 weeks, her skin lesion cleared [77, 78] . In case 143, the skin rash regressed after stopping topical corticosteroids, even without antimicrobial treatment [69] .
Previous reviews of protothecosis have concluded that protothecosis has little tendency toward self-cure [79, 80] . In most reports, once established, protothecosis tends to progress, but there are some exceptions. As noted above, there were three cases that healed or improved with no treatment. While the occasional spontaneous cure may be interesting biologically, we cannot recommend leaving any established Prototheca infection untreated without a good reason. The three cases that healed or improved with no treatment were all skin cases. Case 65, the untreated septicemia, died [70] . In spite of attempted treatment, patients 1, 3, and 19 had progressive skin lesions; and patients 3, 54, 63, 93, 124, 125, 129, 145, 151, and 159 all died [34,37,46 -48,61,81 -93] . Once established, protothecosis is potentially serious, and should be treated unless the risks of treatment outweigh the risks of the infection, considering the patient ' s individual circumstances. If not treated, protothecosis should be observed closely to see whether it will progress or resolve.
Olecranon bursitis and small skin lesions can be treated by surgical excision. All other Prototheca infections require systemic medical treatment. The choice in systemic treatment is between the azoles and amphotericin-B. Amphotericin-B has the best record both in vitro and in vivo . The azoles have had variable results in vitro ; but have often succeeded in treating patients. The azoles are not as toxic as amphotericin-B, and can be given orally. We think they are a reasonable choice for initial treatment for the patient with relatively mild disease. Azoles used systemically to treat protothecosis have included itraconazole, fl uconazole, ketoconazole, and voriconazole. Success rates, as noted above, have been higher for itraconazole and fl uconazole than for ketoconazole; but these differences, while interesting, have not been statistically signifi cant. All these azoles can cause liver toxicity, but ketoconazole has caused liver toxicity more often, and caused hepatitis in protothecosis case 31 [38,94 -96] . We would recommend starting with either itraconazole or fl uconazole.
Voriconazole and posaconazole are new. For voriconazole, both the in vitro and the clinical results so far have been limited and confl icting. We found no reports of any patients treated with posaconazole. These two new azoles need further evaluation before they can be recommended as treatments for protothecosis.
For a patient who has failed treatment with an azole, or for initial treatment of a patient with severe disease, we recommend amphotericin-B IV. Although the differences were not statistically signifi cant, amphotericin-B IV had the highest success rate of any treatment. Given the rarity of protothecosis, it will be diffi cult to accumulate enough cases treated in different ways to achieve statistical signifi cance, and we may have to make treatment decisions based on trends. Amphotericin-B IV has been highly effective, and adding a second drug to it has not been demonstrated to make it any more effective. We would generally recommend using amphotericin-B without a second drug. In the unlikely event that treatment of a patient with amphotericin-B was failing, then we would recommend adding tetracycline. We would recommend treating until the patient is in stable condition without any active infl ammation. Unless toxicity dictates a shorter course, we would recommend treating for at least 1 month.
Intravenous amphotericin-B, alone or in combination, has been used in 40 cases, and is well established as the most effective treatment for protothecosis known at this time. Surprisingly, topical amphotericin-B, alone or in combination, has also had an impressive record for skin infections -four successes out of six evaluable treatments -but this is too few to prove anything. We think further trials of topical amphotericin-B for Prototheca skin infections would be worthwhile. If topical amphotericin-B turns out to be effective for Prototheca skin infections, it would avoid the toxicity of systemic amphotericin-B and also the adverse effects of intravenous therapy. Nystatin is structurally similar to amphotericin-B, and nearly all Prototheca tested have been susceptible in vitro . We think nystatin also deserves consideration as a topical treatment for Prototheca skin infections. We did not fi nd any reports of patients treated with nystatin. While we recommend systemic amphotericin-B for all serious, persistent, or recurrent Prototheca infections, and think that topical amphotericin-B for skin infections should be studied, we would generally recommend against local injections of amphotericin-B. The few times they have been tried, topical azoles and local injection azoles have been and harmless and usually effective. We think they also deserve further consideration for Prototheca skin infections.
The value of in vitro susceptibility testing in the medical treatment of protothecosis remains unsettled. If done, the results should be interpreted with caution. In vitro resistance does not necessarily predict clinical failure. We hope further work on susceptibility testing for Prototheca will improve its predictive value.
For olecranon bursitis, 9 of the 10 evaluable cases have been treated, and cured, with surgery. We could not fi nd any cases of olecranon bursitis treated systemically with either an azole or amphotericin-B. A trial of systemic itraconazole or fl uconazole might be worthwhile. If a month of an oral agent could cure the infection, some patients might prefer this to permanent loss of the olecranon bursa.
The three cases treated with combination treatments including topical heat are interesting and not without biological plausibility. In reporting the fi rst human infections by P. zopfi i and P. wickerhamii , Davies et al . and Klintworth et al . noted that the organisms grew best at 30 -32 ° C, and poorly if at all above 38 ° C [47, 81] . For both P. zopfi i var. zopfi i and P. wickerhamii , Pore reports growth as positive at 25 ° C but variable at 37 ° C [10] . We think topical heat deserves further investigation, particularly for skin infections failing simple medical treatment. When Ueno et al . found ' a novel thermotolerant Prototheca zopfi i var. zopfi i ' that could thrive at 40 ° C, they reported it as quite different from most Prototheca . They found this unusual strain living freely in a hot spring, not causing an infection [97] .
Although P. wickerhamii causes most cases of human protothecosis, P. zopfi i causes a signifi cant minority. There have been too few human P. zopfi i cases to conclude anything about whether the best treatments for P. zopfi i might be different from the best treatments for P. wickerhamii , but in vitro work has suggested there might be differences. We would recommend further in vitro and in vivo experiments looking at drug susceptibilities of P. wickerhamii and P. zopfi i . Until further work is done, we have to recommend the same treatments for P. wickerhamii and P. zopfi i .
